Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
Baker Heart and Diabetes Institute study shows potential of Cardihab technology for cardiac rehabilitation
New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance
ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections
Ferronova and Purdue Research Foundation (PRF) sign licensing agreement for use of Fibroblast Activation Protein (FAP) inhibitor in radiotherapy
Uniseed investee Kinoxis awarded new US grant funding to support clinical development of KNX100 for opioid use disorder
KNX100 is a small molecule in development for the treatment of substance use disorders, including symptoms associated with withdrawal from opioids US$3.6 million awarded to Kinoxis under the US National Institutes of Health National Institute on Drug Abuse’s...